Literature DB >> 889443

Influenza virus infection of hamsters. A model for evaluating antiviral drugs.

H E Renis.   

Abstract

Inoculation of hamsters with influenza virus [A/PR/8/34 HON 1] produces an inapparent infection which can be monitored by virus titrations of nasal washes or of homogenates prepared from trachea or lung. Antibody can be detected in the serum within 7 days following virus inoculation. Hamsters previously infected were found to be resistant to challenge with the same virus. The utility of this model for evaluating anti-influenza drugs was demonstrated with two compounds. Calcium elenolate, a virucidal agent, reduced the virus titers of nasal washes when the drug was given as nose drops near the time of virus inoculation so as to affect high drug concentrations in the nasal passages. Virazole, an inhibitor of virus replication, reduced the virus titers of the nasal washes when multiple drug treatments were given as nose drops in an effort to provide drug during the time of virus replication. The model described may provide a useful means of evaluating potential antiviral during candidates inasmuch as the drug can be delivered directly into the nasal passages in a non-fatal influenza infection in a convenient laboratory animal.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 889443     DOI: 10.1007/bf01314381

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  22 in total

1.  In vitro and in vivo effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) on types 1 and 3 parainfulenza virus infections.

Authors:  R W Sidwell; G P Khare; L B Allen; J G Huffman; J T Witkowski; L N Simon; R K Robins
Journal:  Chemotherapy       Date:  1975       Impact factor: 2.544

Review 2.  The continuing search for antiviral drugs.

Authors:  R A Buchnall
Journal:  Adv Pharmacol Chemother       Date:  1973

3.  Control of acute mycoplasmal and viral respiratory tract disease.

Authors:  R M Chanock
Journal:  Science       Date:  1970-07-17       Impact factor: 47.728

4.  The immune response of hamsters to purified haemagglutinins and whole influenza virus vaccines following live influenza virus infection.

Authors:  R Jennings; C M Brand; C McLaren; L Shepherd; C Potter
Journal:  Med Microbiol Immunol       Date:  1974       Impact factor: 3.402

5.  In vitro antiviral activity of calcium elenolate.

Authors:  H E Renis
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1969

6.  Plaque formation by influenza viruses in monolayers of chicken kidney cells.

Authors:  H A Babiker; R Rott
Journal:  J Gen Virol       Date:  1968-09       Impact factor: 3.891

7.  Pathogenesis of and recovery from respiratory syncytial and influenza infections in ferrets.

Authors:  C A Pinto; R F Haff; R C Stewart
Journal:  Arch Gesamte Virusforsch       Date:  1969

8.  Studies on the mechanisms of influenza virus infection in hamster trachea organ culture. Correlation of reduced viral adsorption with age-related resistance to infection.

Authors:  L J Schiff
Journal:  Arch Gesamte Virusforsch       Date:  1974

9.  In vitro effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses.

Authors:  J H Huffman; R W Sidwell; G P Khare; J T Witkowski; L B Allen; R K Robins
Journal:  Antimicrob Agents Chemother       Date:  1973-02       Impact factor: 5.191

10.  Influenza virus infection in the hamster; a study of inapparent virus infection and virus adaptation.

Authors:  W F FRIEDEWALD; E W HOOK
Journal:  J Exp Med       Date:  1948-09-01       Impact factor: 14.307

View more
  2 in total

1.  Influenza A virus infection of primary differentiated airway epithelial cell cultures derived from Syrian golden hamsters.

Authors:  Celeste M Newby; Regina K Rowe; Andrew Pekosz
Journal:  Virology       Date:  2006-07-31       Impact factor: 3.616

Review 2.  Ribavirin: a clinical overview.

Authors:  H Fernandez; G Banks; R Smith
Journal:  Eur J Epidemiol       Date:  1986-03       Impact factor: 8.082

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.